PMC:7309518 / 14383-14845 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T97","span":{"begin":11,"end":22},"obj":"Body_part"},{"id":"T98","span":{"begin":199,"end":210},"obj":"Body_part"}],"attributes":[{"id":"A97","pred":"fma_id","subj":"T97","obj":"http://purl.org/sig/ont/fma/fma82780"},{"id":"A98","pred":"fma_id","subj":"T98","obj":"http://purl.org/sig/ont/fma/fma82816"}],"text":"eral nerve glycolipids and Campylobacter jejuni or Zika virus that also trigger GBS.1–3 Accordingly, all GBS subtypes (AIDP, AMAN, and MFS) can be expected with COVID-19, necessitating screening for ganglioside antibodies to assess autoimmunity. An interesting therapeutic component in this association is the emerging data that chloroquine, an antimalarial drug under investigation for treating COVID-19, binds with high-affinity sialic acids and GM1 gangliosid"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T39","span":{"begin":5,"end":10},"obj":"Body_part"}],"attributes":[{"id":"A39","pred":"uberon_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/UBERON_0001021"}],"text":"eral nerve glycolipids and Campylobacter jejuni or Zika virus that also trigger GBS.1–3 Accordingly, all GBS subtypes (AIDP, AMAN, and MFS) can be expected with COVID-19, necessitating screening for ganglioside antibodies to assess autoimmunity. An interesting therapeutic component in this association is the emerging data that chloroquine, an antimalarial drug under investigation for treating COVID-19, binds with high-affinity sialic acids and GM1 gangliosid"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T202","span":{"begin":51,"end":55},"obj":"Disease"},{"id":"T203","span":{"begin":80,"end":83},"obj":"Disease"},{"id":"T204","span":{"begin":105,"end":108},"obj":"Disease"},{"id":"T205","span":{"begin":119,"end":123},"obj":"Disease"},{"id":"T207","span":{"begin":125,"end":129},"obj":"Disease"},{"id":"T208","span":{"begin":135,"end":138},"obj":"Disease"},{"id":"T211","span":{"begin":161,"end":169},"obj":"Disease"},{"id":"T212","span":{"begin":396,"end":404},"obj":"Disease"}],"attributes":[{"id":"A202","pred":"mondo_id","subj":"T202","obj":"http://purl.obolibrary.org/obo/MONDO_0018661"},{"id":"A203","pred":"mondo_id","subj":"T203","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A204","pred":"mondo_id","subj":"T204","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A205","pred":"mondo_id","subj":"T205","obj":"http://purl.obolibrary.org/obo/MONDO_0020347"},{"id":"A206","pred":"mondo_id","subj":"T205","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A207","pred":"mondo_id","subj":"T207","obj":"http://purl.obolibrary.org/obo/MONDO_0020349"},{"id":"A208","pred":"mondo_id","subj":"T208","obj":"http://purl.obolibrary.org/obo/MONDO_0007947"},{"id":"A209","pred":"mondo_id","subj":"T208","obj":"http://purl.obolibrary.org/obo/MONDO_0019202"},{"id":"A210","pred":"mondo_id","subj":"T208","obj":"http://purl.obolibrary.org/obo/MONDO_0005851"},{"id":"A211","pred":"mondo_id","subj":"T211","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A212","pred":"mondo_id","subj":"T212","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"eral nerve glycolipids and Campylobacter jejuni or Zika virus that also trigger GBS.1–3 Accordingly, all GBS subtypes (AIDP, AMAN, and MFS) can be expected with COVID-19, necessitating screening for ganglioside antibodies to assess autoimmunity. An interesting therapeutic component in this association is the emerging data that chloroquine, an antimalarial drug under investigation for treating COVID-19, binds with high-affinity sialic acids and GM1 gangliosid"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T105","span":{"begin":56,"end":61},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"eral nerve glycolipids and Campylobacter jejuni or Zika virus that also trigger GBS.1–3 Accordingly, all GBS subtypes (AIDP, AMAN, and MFS) can be expected with COVID-19, necessitating screening for ganglioside antibodies to assess autoimmunity. An interesting therapeutic component in this association is the emerging data that chloroquine, an antimalarial drug under investigation for treating COVID-19, binds with high-affinity sialic acids and GM1 gangliosid"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T78","span":{"begin":11,"end":22},"obj":"Chemical"},{"id":"T79","span":{"begin":199,"end":210},"obj":"Chemical"},{"id":"T80","span":{"begin":329,"end":340},"obj":"Chemical"},{"id":"T81","span":{"begin":345,"end":357},"obj":"Chemical"},{"id":"T82","span":{"begin":358,"end":362},"obj":"Chemical"},{"id":"T83","span":{"begin":431,"end":443},"obj":"Chemical"},{"id":"T84","span":{"begin":438,"end":443},"obj":"Chemical"},{"id":"T85","span":{"begin":448,"end":451},"obj":"Chemical"}],"attributes":[{"id":"A78","pred":"chebi_id","subj":"T78","obj":"http://purl.obolibrary.org/obo/CHEBI_33563"},{"id":"A79","pred":"chebi_id","subj":"T79","obj":"http://purl.obolibrary.org/obo/CHEBI_28892"},{"id":"A80","pred":"chebi_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A81","pred":"chebi_id","subj":"T81","obj":"http://purl.obolibrary.org/obo/CHEBI_38068"},{"id":"A82","pred":"chebi_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A83","pred":"chebi_id","subj":"T83","obj":"http://purl.obolibrary.org/obo/CHEBI_26667"},{"id":"A84","pred":"chebi_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A85","pred":"chebi_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/CHEBI_18216"},{"id":"A86","pred":"chebi_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/CHEBI_61048"},{"id":"A87","pred":"chebi_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/CHEBI_73110"}],"text":"eral nerve glycolipids and Campylobacter jejuni or Zika virus that also trigger GBS.1–3 Accordingly, all GBS subtypes (AIDP, AMAN, and MFS) can be expected with COVID-19, necessitating screening for ganglioside antibodies to assess autoimmunity. An interesting therapeutic component in this association is the emerging data that chloroquine, an antimalarial drug under investigation for treating COVID-19, binds with high-affinity sialic acids and GM1 gangliosid"}

{"project":"LitCovid-PubTator","denotations":[{"id":"503","span":{"begin":27,"end":47},"obj":"Species"},{"id":"504","span":{"begin":51,"end":61},"obj":"Species"},{"id":"526","span":{"begin":199,"end":210},"obj":"Chemical"},{"id":"527","span":{"begin":329,"end":340},"obj":"Chemical"},{"id":"528","span":{"begin":431,"end":443},"obj":"Chemical"},{"id":"543","span":{"begin":161,"end":169},"obj":"Disease"},{"id":"544","span":{"begin":396,"end":404},"obj":"Disease"}],"attributes":[{"id":"A503","pred":"tao:has_database_id","subj":"503","obj":"Tax:197"},{"id":"A504","pred":"tao:has_database_id","subj":"504","obj":"Tax:64320"},{"id":"A526","pred":"tao:has_database_id","subj":"526","obj":"MESH:D005732"},{"id":"A527","pred":"tao:has_database_id","subj":"527","obj":"MESH:D002738"},{"id":"A528","pred":"tao:has_database_id","subj":"528","obj":"MESH:D012794"},{"id":"A543","pred":"tao:has_database_id","subj":"543","obj":"MESH:C000657245"},{"id":"A544","pred":"tao:has_database_id","subj":"544","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"eral nerve glycolipids and Campylobacter jejuni or Zika virus that also trigger GBS.1–3 Accordingly, all GBS subtypes (AIDP, AMAN, and MFS) can be expected with COVID-19, necessitating screening for ganglioside antibodies to assess autoimmunity. An interesting therapeutic component in this association is the emerging data that chloroquine, an antimalarial drug under investigation for treating COVID-19, binds with high-affinity sialic acids and GM1 gangliosid"}

{"project":"LitCovid-PD-GlycoEpitope","denotations":[{"id":"T16","span":{"begin":448,"end":451},"obj":"GlycoEpitope"}],"attributes":[{"id":"A16","pred":"glyco_epitope_db_id","subj":"T16","obj":"http://www.glycoepitope.jp/epitopes/EP0050"}],"text":"eral nerve glycolipids and Campylobacter jejuni or Zika virus that also trigger GBS.1–3 Accordingly, all GBS subtypes (AIDP, AMAN, and MFS) can be expected with COVID-19, necessitating screening for ganglioside antibodies to assess autoimmunity. An interesting therapeutic component in this association is the emerging data that chloroquine, an antimalarial drug under investigation for treating COVID-19, binds with high-affinity sialic acids and GM1 gangliosid"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T107","span":{"begin":232,"end":244},"obj":"Phenotype"}],"attributes":[{"id":"A107","pred":"hp_id","subj":"T107","obj":"http://purl.obolibrary.org/obo/HP_0002960"}],"text":"eral nerve glycolipids and Campylobacter jejuni or Zika virus that also trigger GBS.1–3 Accordingly, all GBS subtypes (AIDP, AMAN, and MFS) can be expected with COVID-19, necessitating screening for ganglioside antibodies to assess autoimmunity. An interesting therapeutic component in this association is the emerging data that chloroquine, an antimalarial drug under investigation for treating COVID-19, binds with high-affinity sialic acids and GM1 gangliosid"}

{"project":"2_test","denotations":[{"id":"32518172-23899233-75850515","span":{"begin":84,"end":85},"obj":"23899233"},{"id":"32518172-26948433-75850516","span":{"begin":86,"end":87},"obj":"26948433"}],"text":"eral nerve glycolipids and Campylobacter jejuni or Zika virus that also trigger GBS.1–3 Accordingly, all GBS subtypes (AIDP, AMAN, and MFS) can be expected with COVID-19, necessitating screening for ganglioside antibodies to assess autoimmunity. An interesting therapeutic component in this association is the emerging data that chloroquine, an antimalarial drug under investigation for treating COVID-19, binds with high-affinity sialic acids and GM1 gangliosid"}